Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes

BACKGROUND AND AIMS: Although landmark clinical trials have demonstrated an increased risk for genitourinary infection (GUI) after initiation of sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy that led to an FDA label warning, real world findings have been inconsistent and evidence specifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Varshney, Navya, Billups, Sarah J., Saseen, Joseph J., Fixen, Cy W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010840/
https://www.ncbi.nlm.nih.gov/pubmed/33854754
http://dx.doi.org/10.1177/2042098621997703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010840/
https://www.ncbi.nlm.nih.gov/pubmed/33854754
http://dx.doi.org/10.1177/2042098621997703

Ejemplares similares